Company intelligence / Profile preview

Nanjing Qingpu Biotechnology

Nanjing, Jiangsu Province, Chinaecosystem.freewayphx.com ↗

Ownership: Private
Employees: ~70
Development stage: Preclinical

Overview

Nanjing Qingpu Biotechnology has launched its first non-addictive analgesic product in China and the US. The lead product has received NDA acceptance in both countries and commercialization revenue is imminent. Two additional products are in Phase II clinical trials. All pipeline projects are first-in-class domestically for their mechanisms and show significant clinical advantages over existing global products.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

QP-5113

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Nanjing Qingpu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Qingpu Biotechnology.

Explore the full profile